Stockscreener 앱 받기
8.00
0.00%
0.00
시간 외 거래:
8.00
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Invesco Ltd. Has $153,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by JPMorgan Chase & Co. - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Could Be Less Than A Year Away From Profitability - simplywall.st
Are Zevra Therapeutics Inc (ZVRA) shares a good deal now? - uspostnews.com
Zevra Therapeutics to Participate in the Citizens Life Science Conference - The Manila Times
Rare Disease Leader Zevra Therapeutics Reveals Growth Strategy at Citizens Conference - Stock Titan
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Geode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Investment Analysis and Advice - news.stocktradersdaily.com
Zevra calls for stockholder support against board influence bid - Investing.com
Zevra Therapeutics (ZVRA) Prepares for 2025 Annual Meeting, Advocates for Board Stability | ZVRA Stock News - GuruFocus
Zevra calls for stockholder support against board influence bid By Investing.com - Investing.com India
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders | ZVRA Stock News - GuruFocus
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - The Manila Times
Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns - Nasdaq
ZVRAZevra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
Zevra Therapeutics (ZVRA) Reveals Key Insights into Niemann-Pick Type C Treatment | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewswire
Breakthrough Study Uncovers MIPLYFFA's Mechanism for Treating Fatal Genetic Disease NPC - Stock Titan
Vanguard Group Inc. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Corebridge Financial Inc. Buys 3,801 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Raymond James Financial Inc. Purchases Shares of 26,916 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Institutional investors may overlook Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) recent US$44m market cap drop as long-term gains remain positive - simplywall.st
Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher - MarketScreener
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves - marketscreener.com
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - citybiz
$150M FDA Voucher Sale Transforms Zevra's Financial Position: Rare Disease Success Story - Stock Titan
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline - MSN
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Brokerages - Defense World
(ZVRA) Technical Data - news.stocktradersdaily.com
Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (NASDAQ:ZVRA) - Seeking Alpha
Quantbot Technologies LP Sells 7,219 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra therapeutics director Corey Watton buys $2,351 in stock By Investing.com - Investing.com Australia
Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener
Zevra Therapeutics Files Preliminary Proxy - The Manila Times
Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan
Charles Schwab Investment Management Inc. Buys 28,148 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
John Bode Bought 33% More Shares In Zevra Therapeutics - simplywall.st
Zevra Therapeutics Independent Director Acquires 33% More Stock - Yahoo Finance
Insider Buying: John Bode Acquires Additional Shares of Zevra Th - GuruFocus
Zevra therapeutics director Bode acquires $79,624 in stock By Investing.com - Investing.com Canada
Zevra therapeutics director Bode acquires $79,624 in stock - Investing.com
ZEVRA THERAPEUTICS Director John B Bode Acquires 10,000 Shares - TradingView
Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Australia
Zevra Therapeutics’ SWOT analysis: stock poised for growth amid rare disease focus By Investing.com - Investing.com South Africa
HC Wainwright Predicts Lower Earnings for Zevra Therapeutics - Defense World
(ZVRA) On The My Stocks Page - news.stocktradersdaily.com
Guggenheim Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World
HC Wainwright Reiterates “Buy” Rating for Zevra Therapeutics (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics (NASDAQ:ZVRA) Earns Overweight Rating from Cantor Fitzgerald - Defense World
0.39%
3.66%
자본화:
|
볼륨(24시간):